Eric J. Daniels
Equibles does not estimate personal net worth.
About Eric J. Daniels
Kiora Pharmaceuticals Inc reported in an 8-K filed April 2, 2026 that Eric J. Daniels resigned as Chief Development Officer, effective April 17, 2026. The proxy statement of Kiora Pharmaceuticals Inc reports total compensation of $957,504 for Eric J. Daniels in fiscal 2025, including a base salary of $452,717. Disclosed compensation is on record for 5 fiscal years.
“On April 1, 2026, Eric J. Daniels, M.D., MBA, the Chief Development Officer of Kiora Pharmaceuticals, Inc. (the "Company"), notified the Company that he will resign as Chief Development Officer effective as of April 17, 2026 (the "Effective Date") to pursue another opportunity.”
Affiliation history
-
Kiora Pharmaceuticals Inc (KPRX)
Proxy statement
Start not stated–2026-04-17
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kiora Pharmaceuticals Inc (KPRX) | MD, MBA Former Chief Development Officer6 | $452,717 | $957,504 |
| 2024 | Kiora Pharmaceuticals Inc (KPRX) | MD, MBA Chief Development Officer6 | $388,212 | $674,053 |
| 2023 | Kiora Pharmaceuticals Inc (KPRX) | MD, MBA Chief Development Officer6 | $338,577 | $669,953 |
| 2022 | Kiora Pharmaceuticals Inc (KPRX) | MD, MBA Chief Development Officer5 | $350,463 | $546,909 |
| 2021 | Kiora Pharmaceuticals Inc (KPRX) | MD, MBA Chief Development Officer5 | $68,382 | $156,082 |